期刊文献+

对我国成本效果阈值确定方法的思考 被引量:5

Considerations of methods for determining cost-effectiveness threshold in China
原文传递
导出
摘要 目的:对成本效果阈值现有的主要确定方法进行分析,寻找适合我国的阈值确定方法,为我国成本效果阈值的确定及应用奠定基础。方法:通过文献综述的方法,对目前主要的成本效果阈值确定方法进行回顾分析和归纳总结,在此基础上找出适合我国的成本效果阈值确定方法。结果:社会意愿支付法、阈值寻找者模式、人均GDP法均对我国成本效果阈值的确定有重要的借鉴意义。结论:建议以阈值寻找者模式为主、以人均GDP法(社会意愿支付法)为参考来确定我国的成本效果阈值,在寻找我国的成本效果阈值期间,可暂时先借鉴人均GDP法确定的经济性评价标准。 Objective: To analyze the main existing methods of cost-effectiveness threshold,and to provide the basis for the determination and use of cost-effectiveness threshold in China.Methods: The main existing methods were analyzed and reviewed retrospectively to find out the appropriate method(s) in China.Results: Social willing-to-pay approach,ICER threshold-searcher-model and GDP per capita approach were very important references to appropriately determine the cost-effectiveness threshold in China.Conclusion: The recommendation for appropriate determination of cost-effectiveness threshold in China is that the ICER threshold-searcher-model can be used as the main determining method,and the GDP per capita approach(social willing-to-pay approach) as the reference.We can temporarily use GDP per capita as a replacement of the real threshold.
作者 宗欣 孙利华
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第24期2857-2860,共4页 Chinese Journal of New Drugs
关键词 成本效果阈值确定方法 社会意愿支付法 阈值寻找者模式 人均GDP法 cost-effectiveness threshold determining method social willing-to-pay methods ICER threshold searcher model GDP per capita
  • 相关文献

参考文献10

  • 1FRANK AS. Valuing health care : costs, benefits, and effective-ness of pharmaceuticals and other medical technologies [ M ].Cambridge: Cambridge University Press, 1995.
  • 2ADRIAN T, CLIVE P, NANCY D. Cost-effectiveness thresholds:economic and ethical issues [ M ]. London : King’s Fund and Of-fice of Health Economics, 2002.
  • 3LAMEIRE N, JOFFE P, WIEDEMANN M. Healthcare systems-an international review: an overview [ J] . Nephrol Dial Trans-plant, 1999,14(Suppl6) :3 -9.
  • 4World Health Organization( WHO). WHOCHOICE [EB/OL].[2011 — 07 - 08 ] . http ://www. who. int/choice/costs/CERthresholds/en/index. html.
  • 5ANTHONY JC, CHRISTOPHER MC , ANDREW HB. The NICEcost-effectiveness threshold: what it is and what that means[ J].Pharmacoeconomics ,2008 ,26 (9) ; 733 - 744.
  • 6Martin Buxton. Looking for willingness-lo-pay ( WTP) thresholdfora QALY-does it make sense? A practical view[ R ]. ISPOR9th Annual European Congress, 31 October 2006, Copenhagen,Denmark.
  • 7ANTHONY JC, CHRISTOPHER MC, ANDREW HB. Searchingfor a threshold, not setting one : the role of the National Institutefor Health and Clinical Excellence) J]. J Health Serv Res Policy,2007,12(1) :56 -58.
  • 8蔡聿雯.贝乐克应用于治疗慢性B型肝炎e抗原阴性病患的成本效果评估[EB/OL] . (2011 -11 -11). http ://ph. med.ncku.edu. tw/? menu = schoolfellow2 _ more&id = 94&kind =schoolfellow2.
  • 9谭延辉.ICER值多少[EB/OL]. (2011 -11 -11). http://www. taspor. org/wp-content/uploads/2008/1 l/2006fall. pdf.
  • 10张玉伟.台湾地区引进人类乳突病毒疫苗的成本效果分析[EB/OL]. (2011 -11- 11). http://ir. ym. edu. tw/ir/bits-tream/987654321/2651/l/39610001_abstract. pdf.

同被引文献56

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部